Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
©2022 American Association for Cancer Research..
Prostate cancer remains the second leading cause of cancer death among American men. Radiotherapy is a potentially curative treatment for localized prostate cancer, and failure to control localized disease contributes to the majority of prostate cancer deaths. Neuroendocrine differentiation (NED) in prostate cancer, a process by which prostate adenocarcinoma cells transdifferentiate into neuroendocrine-like (NE-like) cells, is an emerging mechanism of resistance to cancer therapies and contributes to disease progression. NED also occurs in response to treatment to promote the development of treatment-induced neuroendocrine prostate cancer (NEPC), a highly aggressive and terminal stage disease. We previously demonstrated that by mimicking clinical radiotherapy protocol, fractionated ionizing radiation (FIR) induces prostate cancer cells to undergo NED in vitro and in vivo. Here, we performed transcriptomic analysis and confirmed that FIR-induced NE-like cells share some features of clinical NEPC, suggesting that FIR-induced NED represents a clinically relevant model. Furthermore, we demonstrated that protein arginine methyltransferase 5 (PRMT5), a master epigenetic regulator of the DNA damage response and a putative oncogene in prostate cancer, along with its cofactors pICln and MEP50, mediate FIR-induced NED. Knockdown of PRMT5, pICln, or MEP50 during FIR-induced NED and sensitized prostate cancer cells to radiation. Significantly, PRMT5 knockdown in prostate cancer xenograft tumors in mice during FIR prevented NED, enhanced tumor killing, significantly reduced and delayed tumor recurrence, and prolonged overall survival. Collectively, our results demonstrate that PRMT5 promotes FIR-induced NED and suggests that targeting PRMT5 may be a novel and effective radiosensitization approach for prostate cancer radiotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Molecular cancer therapeutics - 21(2022), 3 vom: 01. März, Seite 448-459 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Owens, Jake L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2022 Date Revised 02.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1535-7163.MCT-21-0103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33562345X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33562345X | ||
| 003 | DE-627 | ||
| 005 | 20231225230254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1535-7163.MCT-21-0103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM33562345X | ||
| 035 | |a (NLM)35027481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Owens, Jake L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2022 | ||
| 500 | |a Date Revised 02.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2022 American Association for Cancer Research. | ||
| 520 | |a Prostate cancer remains the second leading cause of cancer death among American men. Radiotherapy is a potentially curative treatment for localized prostate cancer, and failure to control localized disease contributes to the majority of prostate cancer deaths. Neuroendocrine differentiation (NED) in prostate cancer, a process by which prostate adenocarcinoma cells transdifferentiate into neuroendocrine-like (NE-like) cells, is an emerging mechanism of resistance to cancer therapies and contributes to disease progression. NED also occurs in response to treatment to promote the development of treatment-induced neuroendocrine prostate cancer (NEPC), a highly aggressive and terminal stage disease. We previously demonstrated that by mimicking clinical radiotherapy protocol, fractionated ionizing radiation (FIR) induces prostate cancer cells to undergo NED in vitro and in vivo. Here, we performed transcriptomic analysis and confirmed that FIR-induced NE-like cells share some features of clinical NEPC, suggesting that FIR-induced NED represents a clinically relevant model. Furthermore, we demonstrated that protein arginine methyltransferase 5 (PRMT5), a master epigenetic regulator of the DNA damage response and a putative oncogene in prostate cancer, along with its cofactors pICln and MEP50, mediate FIR-induced NED. Knockdown of PRMT5, pICln, or MEP50 during FIR-induced NED and sensitized prostate cancer cells to radiation. Significantly, PRMT5 knockdown in prostate cancer xenograft tumors in mice during FIR prevented NED, enhanced tumor killing, significantly reduced and delayed tumor recurrence, and prolonged overall survival. Collectively, our results demonstrate that PRMT5 promotes FIR-induced NED and suggests that targeting PRMT5 may be a novel and effective radiosensitization approach for prostate cancer radiotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
| 650 | 7 | |a MEP50 protein, human |2 NLM | |
| 650 | 7 | |a PRMT5 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 650 | 7 | |a Protein-Arginine N-Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 700 | 1 | |a Beketova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Pawar, Jogendra Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Asberry, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xuehong |e verfasserin |4 aut | |
| 700 | 1 | |a Elzey, Bennett D |e verfasserin |4 aut | |
| 700 | 1 | |a Ratliff, Timothy L |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Choo, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Citrin, Deborah E |e verfasserin |4 aut | |
| 700 | 1 | |a Polascik, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bangchen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiaoti |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chenglong |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chang-Deng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer therapeutics |d 2001 |g 21(2022), 3 vom: 01. März, Seite 448-459 |w (DE-627)NLM122520580 |x 1538-8514 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:448-459 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1535-7163.MCT-21-0103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 3 |b 01 |c 03 |h 448-459 | ||